When multiple myeloma relapses

RESPOND with increasing rates of complete response over time with KRd

KRd cumulative rates of complete response

In an exploratory analysis of cumulative rates of CR or better in the ASPIRE trial, KRd showed over a 3 times higher rate of CR or better vs Rd.*1

Adapted from Dimopoulos et al.1

Deep response increased over the duration of treatment, mainly during time of Kyprolis® treatment (around 18 months) and beyond2

Longer median PFS for patients with CR in the ASPIRE trial2

PFS by response category in the group of patients receiving KRd2

Adapted from Stewart et al.2

Deep response (CR or better, vs VGPR or worse) provide your relapsed patients with extra progression-free time2

Kyprolis® has a tolerable safety profile in combination with Rd

*In ASPIRE, cumulative rates of CR or better for KRd and Rd were 31.8% and 9.3%, respectively (descriptive P<0.001).1 Treatment with the KRd regimen for longer than 18 cycles should be based on an individual benefit–risk assessment (limited data on the tolerability/toxicity of Kyprolis® beyond 18 cycles).3 Safety population: time from treatment start.

Please read the SmPC for full comprehensive safety information

References

  1. Dimopoulos MA et al. Presented at the 21st Congress of EHA; 9–12 June 2016; Copenhagen, Denmark. Abstract P275.
  2. Stewart AK et al. N Engl J Med 2015;372:142–152.
  3. Kyprolis® (carfilzomib) Summary of Product Characteristics; 2016.

Terms of Use

The information contained in this site is for European healthcare professionals only.

Kyprolis